Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348) Meeting Abstract
| Authors: | Lim, H. Y.; Heo, J.; Kim, T. Y.; Tai, W. M. D.; Kang, Y. K.; Lau, G.; Kudo, M.; Tak, W. Y.; Watras, M.; Ali, S. K.; Negro, A.; Abou-Alfa, G. K.; Kelley, R. K. |
| Abstract Title: | Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348) |
| Meeting Title: | 2022 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2022 Jan 20-22 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-01 |
| Language: | English |
| ACCESSION: | WOS:000770995900422 |
| DOI: | 10.1200/JCO.2022.40.4_suppl.436 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 436 -- Meeting was conducted online as well as in person -- Source: Wos |
